Danish pharmaceutical company Lundbeck had hoped for quick, efficient results in the third clinical trial with Rexulti as a treatment for agitation in Alzheimer's patients, but this hope was soon extinguished.
That's the lay of the land early on Tuesday, after Lundbeck and partner company Otsuka stated that they would carry on the phase III trial with the drug after having received a new independent analysis of the preliminary results. Lundbeck plans to enroll all 330 patients, which the trial was scheduled for, and it will not discontinue the trial now, after having studied only 255 patients.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
WS Audiology brings in head of EMEA region from Coloplast
The hearing aid manufacturer has appointed Coloplast’s now outgoing president for emerging markets as president for the EMEA region.
Dupixent could dominate pediatric eczema market for up to a decade, analysis finds
Sanofi and Regeneron will be able to call themselves market leaders within atopic eczema treatment for children aged 6 months to 5 for years to come, according to Globaldata.
FDA advisors support approval for Ferring's intestinal infection medicine
All signs indicate that Ferring Pharmaceuticals is on the cusp of being market authorized for its biologic candidate against C. difficile infection.
Pharmacosmos expects massive growth in four years
The company’s new chief executive has ambitions of reaching a DKK 2.5bn (USD 325m) revenue within the time frame.
The Lundbeck Foundation, ATP, LEGO asset manager join forces on secretive project
Three of Denmark’s biggest funds have come together for a yet unknown project, which includes the establishment of three new firms.
CMC Writer 
Regulatory Affairs CMC Specialist 
KLIFO is looking for a Compliance Coordinator for our Glostrup office 
Process Supporter working with SAP 
Senior/lead consultant at Emendo Engineering 
Lab Manager 
Experienced IT Business Solutions Manager for the Danish Medicines Agency 
Scientist Radiochemistry 
Clinical Project Lead 
Nordic Key Account Manager, Hollister & Dansac 
eTMF Manager 
Pharmacovigilance & Regulatory Assistant with an interest in non-fiction 
Vice President, Medical Affairs 
Chief Business Officer